Clinical Trial Update: A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients. [Phase 2]

View source ↗

Summary

ClinicalTrials.gov entry for a Phase II neoadjuvant study evaluating anti-HER2 triple-targeted therapy in combination with CDK4/6 inhibitors for ER-positive, HE…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CDK4/6 inhibitors
• experimental anti-HER2 triple-targeted therapy (anti-HER2 triple-targeted agent)

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING